| My Account | Subscribe | Contact Us | Donate |
Home
-
Diabetes and Adoption
Rachel and her husband chose to adopt a baby instead of meeting the challenges of handling a high risk pregnancy and Rachel’s type 1 diabetes at the same time. She shares their thought process and ultimate happy ending about the decision to bring a child into their lives.
-
Chris Matthews Makes Time for Diabetes
Hosting Hardball on MSNBC and The Chris Matthews Show keep Chris Matthews working long hours. But Matthews got a lesson in priorities and made some life changes when he was diagnosed with type 2.
-
A Chihuahua with Diabetes
Olivia and her dog both have diabetes and today they comfort and encourage each other through the rigors of dealing with the disease. Plus, find out what it means when your domestic pet is diagnosed with diabetes.
-
Smoking and Diabetes
Smoking has severe effects on your diabetes and your health. Learn why diabetes and smoking are an especially bad combination and get some tips from the experts on how to quit.
-
Continuous Glucose Monitors
CGM is a relatively new technology, but the information it provides is invaluable. Find out what CGM offers and whether it could help you.
The must-have resource for physicians, educators and medical professionals who focus on the treatment of diabetes.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Latest Type 2 Medications Articles
Symlin Curtails Fast Food Binges in Weight Loss Study
Jun 27, 2007
As many of us know to our dismay, the desire to chow down fatty, sugary food can be very strong indeed. In a recent six-week study of 88 obese, non-diabetic men and women, Symlin, a synthetic hormone currently used to dampen diabetic blood sugar swings, was found to dampen those very desires.
The study was performed at ten U.S. sites by a number of researchers, including several from Amylin Pharmaceuticals (the makers of Symlin). It required two inpatient stays, one four days long at the beginning and one three days long at the end. For the first two days, all patients received a placebo.
After that, each patient received a shot of either Symlin or a placebo fifteen minutes before every meal. They continued this regimen during the five weeks between inpatient stays, but the fun happened during the stays.
On days 1, 3, and 43, they were offered a delicious buffet of bagels and cream cheese, muffins, fruits, casseroles, cookies and soft drinks, as well as an evening snack of cookies and peanut butter sandwiches. On inpatient days 2, 4, and 44, they were given deep-dish pizzas, ice cream, and soft drinks to assess their tendency to binge eat on sweet and fatty fast foods.
On days 1 and 2, when they were still all on a placebo, every patient apparently ate like there was no tomorrow. Once the Symlin kicked in, however, the eating pattern of the two groups began to diverge. The Symlin group lost an average of 4.5 pounds, while the placebo group lost zip.
On day 3 (the first day that the Symlin group actually got Symlin), they ate 990 fewer calories than they’d eaten on day 1. The placebo group ate only 243 fewer calories. On day 43, plied with the same enticing menu, the Symlin group ate 680 calories less than before Symlin, while the placebo group only ate 191 fewer calories. The drop in calories was primarily due to eating smaller portions, although the Symlin group felt just as satisfied as the placebo group.
On day 44, when the subjects got all the high-fat fast food goodies, the Symlin group reduced their intake by 385 calories compared to the amount they’d eaten on day 2 when they weren’t on Symlin. The placebo group ate only 109 fewer calories.
Because the weight loss attributable to Symlin alone is fairly modest, Amylin Pharmaceuticals is conducting several ongoing studies that test Symlin in combination with other hormones involved in appetite control, such as leptin.
Rat research has indicated that Symlin may restore the sensitivity to leptin that is often lost in obesity, so the hope is that the combination of the two may lead to greater appetite control and weight loss.
Sources: EurekAlert
American Journal of Physiology-Endocrinology and Metabolism
Categories: Diets, Fast Food, Medications, Symlin, Type 1 Issues, Type 2 Issues, Type 2 Medications
Facebook
MySpace 
Digg
Email to a Friend
Send a link to this page to your friends and colleagues.